Kornimate/medical-research-clean huggingface dataset:
attenuation of cardiac effects of arteriovenous fistula creation with losartan

Conditions: Renal Failure; Left Ventricular Hypertrophy

Summary: the primary objective is to determine if the use of losartan, an angiotensin ii receptor blocker, can attenuate left ventricular hypertrophy, independent of its antihypertensive effects, in patients with near end stage chronic kidney disease (ckd) who have an arteriovenous fistula created. secondary outcomes include the impact of the medication on bnp and hyperkalaemia

study design: this is a prospective double blind placebo control 2 arm, randomized (1:1) parallel group study in patients with near end stage renal failure who require creation of an arteriovenous fistula for future haemodialysis. enrolment will be over a period of 12 months. the blinded phase will be for 3 months. the study design is summarized in appendix 1. the study consists of a screening phase, a randomization phase and a treatment phase. patients will be randomized into 2 groups: * group 1 losartan (50mg daily blinded) and 25 mg of atenolol * group 2 placebo (blinded) and 25 mg of atenolol patients: patients must comply with specified inclusion and exclusion criteria. the number of patients used will be sufficient to show a 15% difference in the left ventricular mass (lvm) between the two groups study endpoints: the primary endpoint is the between group difference in lvm from baseline to 1 month. statistical considerations: the analysis will be based upon an 'ancova'-type linear regression model that includes baseline lvm and treatment group as explanatory variables, and final lvm as the outcome variable.

Eligibility criteria:
inclusion criteria: 1. diagnosis of ckd at near-end stage renal failure (ckd stage iv) ( egfr = 15-30 mls/min). 2. age \>18 years of age and \<85 years of age. 3. males and post-menopausal, sterile women. non-pregnant pre-menopausal women should be on adequate contraception and have no intention of becoming pregnant during the duration of the study. 4. at baseline tte lvef\>45% 5. willing and able to give informed consent. exclusion criteria: 1. serum potassium level of more than 5.5 mmol/l 2. acute myocardial infarction or cerebrovascular accident in the previous 6 months. 3. severe uncontrolled hypertension (diastolic bp \>100mmhg or systolic bp \>160 mmhg) 4. evidence or suspicion of renovascular disease. 5. atrial fibrillation 6. evidence or suspicion of collagen disease, cancer, psychiatric disorder that interferes with patient compliance, drug or alcohol abuse, pregnancy, breast feeding and ineffective contraception.

Keywords: arteriovenous fistula hypertrophy losartan
evaluation of colonoscopy with a specific device for the detection of adenomas

Conditions: Colorectal Cancer; Adenoma Colon

Summary: evaluation of colonoscopy with a specific device for the detection of adenomas: multicenter, prospective and randomized study

given the discrepancy in the results of the published studies, the main objective of the present study would be to evaluate, through a multicentric design and with a sufficiently large sample of patients, if there are relevant differences in the adr and in the map between the colonoscopy performed with a device specific (endocuff visiontm) versus standard colonoscopy. secondarily, the number of adenomas, the number of advanced adenomas and the number of serrated lesions in both groups.

Eligibility criteria:
inclusion criteria: all patients must be adults (≥18 years), give their consent for endoscopic exploration, for the study and meet following inclusion criteria: 1. patients with positive immunologic fecal occult blood test (ifobt) for population screening. 2. patients invited to an opportunistic screening colonoscopy or included regional population screening program. 3. patients with a family history of crc and indication of screening colonoscopy. 4. patients with follow-up colonoscopy indication by personal history of adenomas. exclusion criteria: 1. patients with absolute contraindications for colonoscopy (suspicion of intestinal obstruction or perforation, acute diverticulitis suspected or confirmed 6 weeks before the colonoscopy, etc). 2. symptomatic patients with indication of diagnostic colonoscopy. 3. patients with a personal history of crc. 4. patients with a personal history of chronic inflammatory bowel disease (ibd). 5. patients with a known personal history of hereditary crc syndrome: i. no polyposis (lynch syndrome). ii. polypic. 6. patients with suspected attenuated polyposis (\> 20 adenomas) with genetic diagnosis not defined. 7. patients with total or partial colic resection. 8. complete colonoscopy with an adequate preparation (total boston ≥6 with at least score ≥2 per segment) in a period of less than a year 9. pregnant or breastfeeding mothers. 10. patients who have expressed their wish not to participate or who do not have the ability to understand and / or sign informed consent. 11. patients with any serious and uncontrolled medical, psychological, psychiatric, geographic or social problem that could interfere with the participation of the patient in the study or not allow an adequate follow-up and adherence with the protocol and evaluation of the results of the study.

Keywords: colonoscopy adenoma adenoma detection rate
the iron content of ferritin in serum and urine of children with high serum ferritin levels

Conditions: Iron Overload

Summary: a serum ferritin level can reflect the total body iron content, thus a very low serum ferritin is commonly used as an indicator of iron deficiency and a very high serum ferritin is commonly used as a marker of iron overload. ferritin is a shell of protein in which iron is stored. ferritin is an acute phase reactant, and serum ferritin levels can increase during inflammatory conditions. consequently, an elevated ferritin level might mean there is an excess of storage iron, or might simply mean that inflammation has resulted in high levels of the ferritin shell, containing little iron. the research team is able to quantify the amount of iron in ferritin using inductively conducted plasma mass spectrometry, in the heme and iron core laboratory at the university of utah. thus, it can be determined whether in a child with a very high serum ferritin level, that ferritin is loaded with iron or is actually very low in iron. neonates and young children with certain liver disorders characteristically have a very high serum ferritin level. these conditions are gestational alloimmune liver disease (gald) and hemophagocytic lymphohistiocytosis (hlh). it is not clear what the iron content of the ferritin is in these neonates. knowing this will be a step toward understanding whether the pathogenesis of these conditions involves iron overload. additionally, if urine ferritin and iron levels correlate with serum ferritin and iron levels, urine may be used as a non-invasive way to monitor iron status. in this study, serum and urine samples will be collected from children with high serum ferritin levels and confirmed iron toxicity. both ferritin and iron content within ferritin will be measured in the serum and urine samples and compared for correlation.


Eligibility criteria:
inclusion criteria: * children with ferritin levels \> 1000 ng/ml exclusion criteria: * none
safety and efficacy study of abt-089 in adults with mild to moderate alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the purpose of this study is to test if the investigational medication abt-089 is a safe and effective treatment for alzheimer's disease.


Eligibility criteria:
inclusion criteria: * patient has mild to moderate alzheimer's disease * patient has been receiving a stable dose of an acetylcholinesterase inhibitor * patient has a mmse score between 12 and 26 * patient has a mhis score of less than or equal to 4 * females must be postmenopausal for at least two years or surgically sterile * patient has an identified, reliable, caregiver who will support him/her to ensure compliance with treatment and will accompany them to each outpatient visit exclusion criteria: * patient is living in a nursing home * patient has a history of any significant neurologic disease other than alzheimer's disease * patient has any uncontrolled medical illness * patient uses non-prescribed drugs of abuse or has a history of drug or alcohol abuse/dependence

Keywords: mild to moderate alzheimer's disease, memory, cognition, dementia
dgb-01 effects on endurance exercise

Conditions: Fatigue

Summary: the purpose of this research is to evaluate the effects of dgb-01 on performance of a 40-km time trial in trained male cyclists. the investigators believe that dgb-01 will improve performance on the time trial as measured by a reduction in the amount of time required to complete the distance, using a computerized cycle ergometer.


Eligibility criteria:
inclusion criteria: * healthy males who are trained cyclists with a maximal oxygen uptake relative to body weight equal to or greater than 45 ml o2/kg/min. * subjects must be in the competitive phase of their annual training cycle. * between ages of 18-60 * availability- commitment of the subject/expected participation in the study for 97 days. exclusion criteria: * specific allergy to milk proteins (this is different from lactose intolerance) * use of immunosuppressive medication in the case of organ transplants * planned surgeries. * kidney disorders * use of antihypertensive medications * cardiovascular disease * abnormal bun, creatinine, hemoglobin, or hematocrit * body weight greater than 285 pounds * a protein-restricted diet * subjects currently using dry whey protein supplements, n-acetylcysteine, or alpha-lipoic acid supplements. the wash-out period is 1 month for any of these supplements. * all medications that can interfere with muscle mass such as corticosteroids (e.g. prednisone), testosterone replacement or anabolic drugs such as megace

Keywords: ergogenic aid exercise endurance high performance time trial performance glutathione
anchors alcohol & sexual health study: uh3 project

Conditions: Alcohol Use, Unspecified; Substance Use; Sex Behavior

Summary: 80 young adult men will complete an initial survey and receive 1 of 2 types of alcohol and sexual health education and information to encourage prevention of alcohol-related problems, hiv and other sexually transmitted infections (stis). participants will then take pre-exposure prophylaxis (prep) for hiv prevention and complete a daily 5-minute, telephone-based interactive voice response (ivr) assessment of alcohol/substance use, sexual behavior and prep taking for 30 days. medication will all be active prep. there is no placebo control in this study. follow-up will occur after 30-days and 6-months later.


Eligibility criteria:
inclusion criteria: * ability to read and write english * consumption of 5 or more drinks per drinks in a day at least once in the past 30-days * sexual intercourse with another man without condom use at least once in the past 30 days * hiv seronegative at medical screening * report currently taking prep willingness to take prep exclusion criteria: * history of clinically significant withdrawal from alcohol, defined as any one of the following: a) a lifetime history of seizures, delirium, or hallucinations during alcohol withdrawal; b) a clinical institute withdrawal assessment scale score \> 8; c) a report of drinking to avoid withdrawal symptoms in the past 12 months; or d) a lifetime history of medical treatment for withdrawal. * self report injection drug use * dsm-5 criteria for moderate or severe current substance use disorder besides alcohol and nicotine. * serious psychiatric symptoms * use of medications that interfere with prep including diuretics, nephrotoxic drugs, non-steroidal anti-inflammatory drugs, antiretroviral drugs or other drugs that may interfere with tenofovir excretion * active hepatitis b infection * the following medical exclusions: serious or life-threatening conditions; inadequate biochemical, hepatic, hematologic, or pancreatic function according to laboratory testing * participant reports currently taking injectable prep
community-based kiosks for hearing screening and education

Conditions: Hearing Loss

Summary: the overall goal of the project is to evaluate innovative, cost-effective, community-based automated hearing screening and education methods to motivate individuals with mild-to-moderate hearing loss to enter the hearing healthcare system.


Eligibility criteria:
inclusion criteria: : * some subjects will have a complaint of hearing difficulty without a recent hearing evaluation exclusion criteria: * for all groups: minimum age 18 years. no current hearing aid use

Keywords: hearing test, audiology, healthcare utilization, patient education, hearing screening
fluorouracil implants used for intraperitoneal chemotherapy during operation for treatment of phase iii gastric cancer.

Conditions: DSF

Summary: sinofuan is a kind of fluorouracil implants for intraperitoneal chemotherapy during operation for treatment of gastric cancer. the indication has bee approved by chinese fda. the study is a post-marketing study. the subjects will be divided into two groups (group a and group b ). the subject in group a will receive d2 radical gastrectomy(r0),sinofuan during operation and 6 cycles of xelox adjuvant chemotherapy.the subject in group b will receive d2 radical gastrectomy(r0),and 6 cycles of xelox adjuvant chemotherapy. the subject's benefits from sinofuan will be analyzed through comparing 3 years dfs of two groups.


Eligibility criteria:
inclusion criteria: 1. primary gastric cancer, phase iii 2. d2 radical gastrectomy(r0) 3. 18 year old or above 4. kps≥70%； 5. suitable hematologic function: anc≥1.5×109/l, plc≥80×109/l 6. suitable liver function: total bilirubin≤1.5×normal uln, ast and alt≤2.5×normal uln. 7. suitable renal function: cr≤1.5×normal uln,or ccr≥50 ml/min 8 .for the female subject, pregnancy test must be negative in 27 hours before enrollment . 9. the authorized icf must be signed exclusion criteria: 1. non-initial gastric cancer； 2. having the other uncontrolled diseases. 3. obvious loss of weight ( more than 10% within 6 weeks ) 4. the female in pregnancy or feeding. 5. contraindication to study drug 6. participating in other clinical trial and at the time of treatment period.
omega-3 fatty acids, the omega-3 index, and atherosclerosis

Conditions: Atherosclerosis

Summary: an increase in intake of omega-3 fatty acids should increase the omega-3 index. current evidence indicates that this may lead to a reduction in risk for sudden cardiac death and atherosclerotic diseases like myocardial infarction. the aim of the study is to investigate, how supplementing a convenience drink with omega-3 fatty acids influences the omega-3 index, as compared to an unsupplemented matching convenience drink. palatability and safety of the drink are also to be assessed.


Eligibility criteria:
inclusion criteria: 1. subjects must meet the current guideline criteria for atherosclerosis, like coronary, peripheral or carotid artery disease, like previous myocardial infarction or acute coronary syndrome, coronary revascularization (operation or transluminally), or positive angiography or ultrasound. 2. age: 30 - 75 years 3. low omega-3 index (\<5%) 4. subjects must have adequate fluency in german or english to complete baseline and follow-up interviews. 5. stable intake of food containing epa+dha before and during study 6. subjects must be able and willing to give written informed consent, and to comply with study procedures. exclusion criteria: 1. subjects for whom the intake of omega-3 fatty acids is mandatory according to recent treatment guidelines or who take omega-3 fatty acids supplements on a regular basis. 2. patients consuming \>2 portions of fatty fish / week 3. patients with serious bleeding disorder. use of platelet inhibitors or anticoagulation with a target inr of 2.0 - 3.0 is not an exclusion criterion. 4. subjects with any acute and life-threatening condition, such as collapse and shock, acute myocardial infarction (last three months), stroke, embolism. 5. subjects with significant medical co-morbidity, seriously limiting life expectancy or insulin-treated diabetes mellitis or a bmi\>30 6. allergy/intolerance or history of hypersensitivity to components of study intervention, like lactose. 7. pregnant subjects - due to any possible teratogenic effects of study nutrition on the fetus - and breastfeeding subjects. in addition, women of childbearing potential who will not practice a medically accepted method of contraception will be excluded. 8. subjects who, in the investigator's judgement, will not likely be able to comply with the study protocol or with known drug- or alcohol abuse/dependence in the past 2 years. 9. use of any investigational agents within 30 days prior to t0

Keywords: omega-3 fatty acids dietary supplementation atherosclerosis
efficacy of nasal spray calcitonin on recurrence of aggressive central giant cell granuloma

Conditions: Central Giant Cell Granuloma

Summary: the main objective of this randomised clinical trial is to is to compare the frequency of recurrence between patients who received nasal spray calcitonin after curettage of central giant cell granuloma and without it.

a total of 24 patients with aggressive central giant cell granuloma (cgcg )will be selected . all examinations were performed by calibrated clinicians and gender, age, medical history, symptoms, lesion size and site, disease duration and form of treatment were recorded for all participant. radiographic examination with cone beam computed tomography (cbct) and panoramic radiograph was done for all patients. all patients were randomly assigned to one of two treatment groups; 2 weeks after the biopsies were taken. the case group (n =12 with) underwent 200 iu/day ones a day for 3 months after the surgeries. conservative curettage surgical procedure was done for them. while placebo was treated by curettage of cgcgs and received a placebo ones a day for 3 months after surgeries.. patients were followed up by a maxillofacial surgeon who did not participated in surgeries.none of surgeons did not aware about the research before and during the operations.patients were blinded from the drugs which they received after surgeries. all patients were follow up for 5 years after operations. recurrence lesions were documented by clinical and radiographical examinations and proved by histopathological evaluation.

Eligibility criteria:
inclusion criteria: * clinical and histopathological diagnosis of aggressive cgcg based on accepted criteria established by chuong etal normal level of calcitonin and serum parathyroid hormone(pth) patients of both sexes between 13 to 30 year's old patients who gave written informed consent patients who were willing for evaluation in the fallow up session primary size of the lesion should be more than 5 cm in cbct exclusion criteria: * participants demonstrating a systemic disease which affects bone healing,brown tumor ,pregnancy , recently corticosteroid therapy , previous surgical intervention for cgcg or refused study enrollment and whom they could not continue the study for private or social reasons were excluded from the study sample.
a study to evaluate efficacy and safety of sage-547 in participants with severe postpartum depression (547-ppd-202b)

Conditions: Postpartum Depression

Summary: the purpose of this study was to determine if sage-547 injection infused intravenously at up to 90 micrograms per kilogram per hour (μg/kg/h) for 60 hours reduces depressive symptoms in participants with severe postpartum depression (ppd) compared to placebo injection as assessed by the change from baseline in hamilton rating scale for depression (ham-d) total score.


Eligibility criteria:
key inclusion criteria: * participants must have ceased lactating at screening; or if still lactating or actively breastfeeding at screening, agreed to temporarily cease giving breastmilk to their infant(s) from just prior to receiving study drug through nine days (day 12) after the end of the infusion * participants had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by structured clinical interview for dsm-iv axis i disorders (scid-i) * participant had a ham-d total score of ≥26 at screening and day 1 (prior to dosing) * participant was ≤6 months postpartum at screening * participant was amenable to iv therapy key exclusion criteria: * active psychosis * attempted suicide associated with index case of postpartum depression * medical history of bipolar disorders, schizophrenia, and/or schizoaffective disorder. note: other protocol-defined inclusion/exclusion criteria applied.

Keywords: severe postpartum depression sage-547
shear stress in the arteries of the lower limbs during exercise in patients with peripheral arterial disease

Conditions: Peripheral Arterial Disease

Summary: the aim of the study will be to evaluate shear stress and blood flow parameters in lower limb arteries during arm cycle ergometer exercise in participants with peripheral artery disease. twenty patients participants with peripheral artery disease and claudication symptoms will be recruited. participants will perform 3 experimental sessions in random order. iarm-cranking (15 sets of two minutes exercise), warm water foot immersion, and control. during the interventions, blood pressure and heart rate will be assessed every 6 minutes. measurements of arterial diameter, blood flow, anterograde and retrograde shear stress of the femoral artery will be evaluated using a two-dimensional ultrasound device with spectral doppler.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of peripheral artery disease or ankle-brachial index less than 0.90 in one or both limbs * do not present peripheral neuropathy; * be able to exercise after medical approval * aged 50 or over. exclusion criteria: * medication change during the study * health problems that contraindicates the practice of physical exercise.

Keywords: exercise arm-cranking vascular function
reducing disabilities in alzheimer's disease (rdad) translation in area agencies on aging (aaas)

Conditions: Alzheimer's Disease; Dementia; Memory Impairment; Cognitive Impairment

Summary: the university of washington's northwest research group on aging is partnering with area agencies on aging (aaa) in washington and oregon to complete this translational investigation of rdad (reducing disabilities in alzheimer's disease). rdad is an evidence-based program with demonstrated efficacy in helping older adults with dementia maintain physical function and remain physically and mentally healthy. this study asks two questions: 1) can aaa partners successfully translate and implement rdad, and 2) is aaa implementation of rdad effective in producing desired outcomes among agencies, providers, and older adults with dementia and their family members. this study is being conducted in washington and oregon states.


Eligibility criteria:
inclusion criteria: care recipients must * have a diagnosis of dementia * be 65 years of age or older * currently exercise no more than 150 minutes a week and not regularly participate in a formal exercise program. caregivers must * live in the community * provide care to the care recipient with dementia exclusion criteria: either care-recipient or caregiver must not * plan to move to a long-term residential care setting within 6 months of enrollment. * plan to move from the study geographic area within 4 months of enrollment. * have a known terminal illness (with death anticipated within the next 12 months) * have had a hospitalization for a psychiatric disorder in the 12 months prior to baseline * be actively suicidal, hallucinating, or delusional * be blind, deaf, or not ambulatory

Keywords: dementia alzheimer's disease exercise caregiver behavior modification